Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi
Summary
Meanwhile, Ohio voters rejected the latest legislative attempt to curb drug prices, Maine residents supported Medicaid expansion, and patient advocates campaigned for changes to the Republican tax bill.—Amgen (NYSE: AMGN) is the latest big pharmaceutical company taking an axe to its R&D operations, cutting 200 people from its Thousand Oaks, CA, headquarters, and in South San Francisco, STAT reported.—Shares of Five Prime Therapeutics (NASDAQ: FPRX) fell more than 34 percent after the company offered the first glimpse of data from a small study combining its experimental drug cabiralizumab with Bristol-Myers Squibb’s (NYSE: BMY) nivolumab (Opdivo) in pancreatic cancer patients.—The FDA also cleared Keryx Pharmaceuticals (NASDAQ: KERX) to sell ferric citrate (Auryxia) to patients with iron deficiency anemia and chronic kidney disease who aren’t on dialysis.—Merck (NYSE: MRK) won FDA approval of letermovir (Prevymis), a drug meant to prevent the deadly cytomegalovirus infections that can occur in patients who get stem cell transplants.
Classifications
AskAI Classifications
LabelsLinked Companies
